Intravitreal 4D-150DME Clinical Trial: Part 1Interim 32-week Results January 10, 2025 ​ EXHIBIT 99.1

Legal Disclaimer This Presentation contains forward looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Presentation, including statements regarding our clinical development plans, strategy, future operations, future financial position, prospects, plans, objectives of management, and implied and express statements regarding the therapeutic potential, clinical benefits of and market potential of our product candidates are forward looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “target,” “should,” “would,” and similar expressions are intended to identify forward looking statements, although not all forward looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in these forward looking statements, and you should not place undue reliance on these forward looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward looking statements. In addition, the forward looking statements included in this Presentation represent our views as of the date of this Presentation. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward looking statements in the future, we specifically disclaim any obligation to do so. These forward looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Presentation. This Presentation discusses our product candidates that are under preclinical study and in clinical trials, and which have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic use for which they are being studied. This Presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities.

4D-150 continues to be well tolerated: No intraocular inflammation observed at any timepoint or dose level All patients completed the 16-week topical steroid taper on schedule and remained completely off steroids No hypotony, endophthalmitis, vasculitis, choroidal effusions or retinal artery occlusions 4D-150 (3E10 vg/eye, n=9) 32-week efficacy results: Sustained gain in BCVA: +8.4 letters Sustained reduction of CST: –194 µm 86% reduction in injection burden vs. projected on-label aflibercept 2mg Q8W 61% reduction in injection burden vs. 1E10 vg/eye, dose response observed FDA alignment: Single Phase 3 clinical trial acceptable for BLA submission in DME, based on review of interim data from SPECTRA and PRISM and planned global Phase 3 program for wet AMD Company may proceed to Phase 3 per FDA feedback, SPECTRA Part 2 no longer needed Next steps: 3E10 vg/eye selected as Phase 3 dose Detailed results to be presented in corporate webcast on February 10, 2025 SPECTRA 52-week interim data update: Mid-2025 at scientific conference Positive Interim Data & FDA Feedback Supports Advancement of 4D-150 to Phase 3 in DME Interim data support potential for maintenance of vision and anatomy improvements with substantially fewer injections than standard of care Additional details at Corporate Webcast February 10, 2025 Data cutoff date, December 13, 2024. DME, diabetic macular edema; BCVA, best corrected visual acuity; CST, central subfield thickness.

Part 1: Designed to Enroll Patients with High CST and Employed Stringent Supplemental Criteria, with Focus on Safety & Dose Selection *Assessed by SD-OCT and confirmed by independent reading center. †Safety and tolerability (frequency and severity of treatment emergent adverse events). CST, central subfield thickness: defined as thickness of 1mm area from ILM to BM. Supplemental Aflibercept Criteria (starting at Week 8) CST increase ≥50 μm Injections continue until change in CST is ≤30 μm on 2 consecutive visits or CST is ≤325μm Primary endpoint† Durezol® 16-week taper starting at Day -3 Baseline Diagnosis within 2 years, CST ≥350 μm (includes treatment naïve) Confirmed anti-VEGF response (CST decrease ≥40 μm at Week –1 versus Week –8)* Key Eligibility Criteria Evaluate safety & tolerability Identify dose level for further evaluation Key Objectives 32-week Results(40 weeks from baseline) Reference for Supplemental Aflibercept

SPECTRA Disease Activity Criteria for Supplemental Treatment Are Stringent Compared to Other Trials and Did Not Require Vision Decrease *After Week 24. †After Week 12. ‡After Week 8. BCVA, best corrected visual acuity; CST, central subfield thickness; ETDRS, Early Treatment Diabetic Retinopathy Study. 1. Korobelnik et al. Ophthalmology 2014;121:2247–54. 2. Brown et al. Lancet 2024;403:1153–63. 3. Wykoff et al. Lancet 2022;399:741–55. 4. EyePoint Corporate Presentation, October 2024. Product Trial Disease Activity Criteria for Supplemental Treatment or Shortened Dose Interval VIVID/VISTA1 ≥10 letter loss on 2 consecutive visits or ≥15 letter loss at any visit from the best previous measurement AND BCVA worse than baseline​* PHOTON2 >10 letter loss in BCVA from Week 12 due to persistent or worsening DME AND >50 µm increase in CRT from Week 12 YOSEMITE/RHINE3 ≥5 letter loss in BCVA AND ≥10% increase in CST from reference CST ≥20% increase in CST from reference CST independent of any BCVA change VERONA4 ≥10 letter loss in BCVA due to DME 5-9 letters loss in BCVA AND >75 µm of new fluid at two consecutive visits ≥100 µm increase in CST (new fluid) vs. baseline Lack of 10% reduction in CST compared to baseline† 4D-150 SPECTRA Part 1 ≥50 µm increase in CST‡ (supplemental injections continue until change in CST is ≤30 µm on 2 consecutive visits or CST ≤325 µm)

Study Population: Baseline CST, BCVA, and Prior Treatment Status Balanced Across Dose Arms BCVA, best corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study. 1 patient in 1E10 vg/eye arm terminated the study due to death unrelated to 4D-150 prior to completion of a post-baseline assessment 3E10 vg/eye (n=9) 1E10 vg/eye (n=12) 5E9 vg/eye (n=1) Total (N=22) Central subfield thickness, mm Mean (range) 513 (382–671) 488 (356–669) 515 499 (356–671) BCVA, ETDRS letters Mean (range) 63 (41–79) 62 (32–84) 68 63 (32–84) Treatment Experienced, n (%) 7 (78) 9 (75) 0 16 (73)

SPECTRA Designed With Fewer Loading Doses and Enrolled Population With High CST and Majority Treatment Experienced CST, central subfield thickness; BCVA, best corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study. Sources: 1. Korobelnik et al. Ophthalmology 2014;121:2247–54. 2. Brown et al. Lancet 2024;403:1153–63. 3. Wykoff et al. Lancet 2022;399:741–55. 4. EyePoint Corporate Presentation, October 2024. *Given concurrently with DURAVYU. Anti-VEGF Loading Doses Mean CST at Baseline (µm) Treatment Experienced at Baseline (%) Selected Studies: 4D-150 PHOTON2 VIVID/VISTA1 YOSEMITE/RHINE3 VERONA4 VIVID VISTA Phase 3 Phase 1/2

4D-150 Continues to be Well Tolerated Data cutoff date, December 13, 2024. 4D-150 continues to be well tolerated with no intraocular inflammation at any timepoint at any dose level All patients completed the 16-week topical steroid taper on schedule and remained completely off steroids No hypotony, endophthalmitis, vasculitis, choroidal effusions or retinal artery occlusions

No Intraocular Inflammation and All Patients Completed Prophylactic Topical Steroids on Schedule and Remained Completely Off Steroids Data cutoff date, December 13, 2024. *Excludes patient with early termination due to death (unrelated to 4D-150) prior to completion of a post-baseline assessment. NEI, National Eye Institute; SUN, Standardization of Uveitis Nomenclature; TR, trace (not observed); PC, pigmented cells (not observed); X, missed visit. Anterior Chamber Cells Vitreous Cells X X X X 0 2 8 12 16 20 24 28 32 X X X X 0 2 8 12 16 20 24 28 32 Week X 0 (none) 1+ 3+ 4+ 2+ 5E9 vg/eye Topical Corticosteroid NEI/SUN Score 3E10 vg/eye (N=9) 1E10 vg/eye* (N=11) Missed Visit

4D-150 3E10 vg/eye: Sustained Improvement in Visual Acuity Through 32 Weeks (+8.4 Letters vs Baseline) Week Supplemental Injections**, n 3E10 vg/eye (n=9) 0 0 2 0 2 1 0 0.6 1E10 vg/eye (n=11) 1 2 2 4 2 1 3 1.4 +8.4 +7.1 Aflibercept Mean per patient Data cutoff date, December 13, 2024. *Excludes patient with early termination due to death (unrelated to 4D-150) prior to completion of a post-baseline assessment. **No patient in 3E10 or 1E10 vg/eye arm would have received a supplemental injection based on disease activity measurement at time of first supplemental injection based on disease activity worsening criteria in VIVID/VISTA or PHOTON. BCVA, best corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study. Estimated gene expression ramp-up period 2 4D-150 Illustrative residual effect of Week 2 loading dose

Eylea Phase 3 Studies in DME1 Compared 5 Loading Doses + Q4W or Q8W vs. Laser On-label Eylea Improves CST ~165 µm But Requires High Treatment Burden 1. Korobelnik et al. Ophthalmology 2014;121:2247–54. Aflibercept 2mg 5 Load + Q8W Eylea consistently achieved CST improvements of ~165 µm in DME patients Eylea saw CST rebounds ~8 weeks after last dose of the loading dose regimen, rebounds continue in Q8W arms 1 2 1 1 2 2

4D-150 3E10 vg/eye: Sustained Improvement in Anatomic Control Through 32 Weeks (–194 µm vs Baseline) -194 -153 Data cutoff date, December 13, 2024. *Excludes patient with early termination due to death (unrelated to 4D-150) prior to completion of a post-baseline assessment. **No patient in 3E10 or 1E10 vg/eye arm would have received a supplemental injection based on disease activity measurement at time of first supplemental injection based on disease activity worsening criteria in VIVID/VISTA or PHOTON. CST, central subfield thickness. Supplemental Injections**, n 3E10 vg/eye (n=9) 0 0 2 0 2 1 0 0.6 1E10 vg/eye (n=11) 1 2 2 4 2 1 3 1.4 Mean per patient 4D-150 2 Aflibercept Illustrative residual effect of Week 2 loading dose Estimated gene expression ramp-up period

3E10 vg/eye Post-loading Phase: 86% Reduction in Treatment Burden vs. Projected On-label Aflibercept 2mg Q8W; Dose Response in Favor of 3E10 Data cutoff date, December 13, 2024. *Excludes patient with early termination due to death (unrelated to 4D-150) prior to completion of a post-baseline assessment. **Excludes n=1 patient who did not receive the Week 2 aflibercept. This patient received 1 supplemental injection through 32 weeks. Mean cumulative function from Cox proportional hazard regression model for recurrent events was used to estimate the mean cumulative number of supplemental aflibercept injections. Loading Phase 1 injection 2 injections 0 injections Cumulative Injections(Weeks 8–32) 3E10 vg/eye (n=9) 0.6 1.4 4.0 86% reduction vs. projected on-label aflibercept 2mg Q8W 5 of 8 Injection-freein patients treated per protocol** 61% reduction vs. 1E10 vg/eye

4D-150 continues to be well tolerated: No intraocular inflammation observed at any timepoint or dose level All patients completed the 16-week topical steroid taper on schedule and remained completely off steroids No hypotony, endophthalmitis, vasculitis, choroidal effusions or retinal artery occlusions 4D-150 (3E10 vg/eye, n=9) 32-week efficacy results: Sustained gain in BCVA: +8.4 letters Sustained reduction of CST: –194 µm 86% reduction in injection burden vs. projected on-label aflibercept 2mg Q8W 61% reduction in injection burden vs. 1E10 vg/eye, dose response observed FDA alignment: Single Phase 3 clinical trial acceptable for BLA submission in DME, based on review of interim data from SPECTRA and PRISM and planned global Phase 3 program for wet AMD Company may proceed to Phase 3 per FDA feedback, SPECTRA Part 2 no longer needed Next steps: 3E10 vg/eye selected as Phase 3 dose Detailed results to be presented in corporate webcast on February 10, 2025 SPECTRA 52-week interim data update: Mid-2025 at scientific conference Positive Interim Data & FDA Feedback Supports Advancement of 4D-150 to Phase 3 in DME Interim data support potential for maintenance of vision and anatomy improvements with substantially fewer injections than standard of care Additional details at Corporate Webcast February 10, 2025 Data cutoff date, December 13, 2024. DME, diabetic macular edema; BCVA, best corrected visual acuity; CST, central subfield thickness.

THANK YOU 5858 Horton Street, Suite 455 | Emeryville, California 94608 (510) 505-2680 | [email protected] IR.4DMT.com | LinkedIn

On-label Aflibercept Improves CST by ~150-180 µm with 7 Total Injections Through 40 Weeks; Rebound Observed at Week 24 Despite 5 Loading Doses 1. Korobelnik et al. Ophthalmology 2014;121:2247–54. 2. Brown et al. Lancet 2024;403:1153–63. 3. Wykoff et al. Lancet 2022;399:741–55. PHOTON2 Aflibercept 2mg Q8W results through week 40achieved with 7 injections Despite 5 loading doses, rebound observed 8 weeks later 1 1 3 3